In clinical trials, PARP inhibitors are mainly concentrated in cancer patients with homologous recombination repair defects, including breast cancer and ovarian cancer patients with BRCA1 and BRCA2 mutations (gBRCA1/2m). This evidence concerns the gene BRCA1 and ovarian carcinoma.